Valuation: Rezolute, Inc.

Market Cap 481M 416M 391M 355M 667M 45.85B 679M 4.57B 1.79B 23B 1.8B 1.76B 76.55B P/E 2026 *
-6.57x
P/E 2027 * -7.08x
Enterprise Value 481M 416M 391M 355M 667M 45.85B 679M 4.57B 1.79B 23B 1.8B 1.76B 76.55B EV / Sales 2026 *
-
EV / Sales 2027 * 209x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 week-2.13%
Current month-2.54%
1 month-2.95%
3 months+38.14%
6 months+19.79%
Current year+94.92%
1 week 4.44
Extreme 4.44
4.88
1 month 4.14
Extreme 4.14
5.4
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap.
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.13%-28.90%+215.07% 481M
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-3.13%+32.57%+60.59% 54.43B
-2.05%-6.65%+0.71%+451.67% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
+1.05%+2.08%-17.46%-12.93% 23.14B
+0.10%+7.99%+41.01%-20.48% 18.65B
+3.81%+16.28%+270.78%+488.06% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
+1.24%-1.84%+33.13%+138.10% 12.54B
Average -0.32%+2.45%+46.51%+200.10% 26.69B
Weighted average by Cap. -1.12%+1.71%+50.81%+159.75%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.87M 1.7M 3.2M 220M 3.25M 21.93M 8.58M 110M 8.65M 8.46M 367M
Net income -72.7M -62.86M -59.1M -53.73M -101M -6.94B -103M -692M -271M -3.48B -273M -267M -11.58B -75.12M -64.95M -61.07M -55.52M -104M -7.17B -106M -715M -280M -3.6B -282M -276M -11.97B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
14/08/26 $4.600 0.00% 654,740
13/08/26 $4.600 -2.13% 800,613
12/08/26 $4.700 +1.73% 2,391,287
11/08/26 $4.620 -1.28% 641,977
10/08/26 $4.680 -0.21% 756,463
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.600USD
Average target price
7.667USD
Spread / Average Target
+66.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock